Progress of cytotoxic T lymphocyte-associated antigen-4 inhibitors in treatment of melanoma
10.3760/cma.j.cn115355-20250512-00228
- VernacularTitle:细胞毒T淋巴细胞相关抗原4抑制剂治疗黑色素瘤的研究进展
- Author:
Renkai ZHI
1
;
Mingjin YANG
1
;
Ha ZHU
1
Author Information
1. 海军军医大学免疫学教研室暨免疫与炎症全国重点实验室，上海 200433
- Publication Type:Journal Article
- Keywords:
Melanoma;
Immune checkpoint inhibitors;
Immunotherapy;
Adverse reactions
- From:
Cancer Research and Clinic
2025;37(8):637-640
- CountryChina
- Language:Chinese
-
Abstract:
Melanoma is characterized with high heterogeneity and invasiveness. The advent of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors have shown the obvious therapeutic efficacy in the treatment of melanoma patients, which promotes the progression of melanoma immunotherapy. However, therapy resistance caused by immune escape of melanoma and immune-related adverse events caused by treatment have limited the therapeutic effects of CTLA-4 inhibitors, which have become a clinical challenge. This article reviews the current role of CTLA-4 inhibitors in melanoma therapy, aiming to provide references for clinical immunotherapy strategies for melanoma.
